NANTES, France--(BUSINESS WIRE)--Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE) today announced the submission of an Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of Tedopi® in advanced or metastatic pancreatic cancer. The trial will compare Tedopi®, 10 neoepitopes associated to activate cytotoxic T-lymphocytes, in combination with nivolumab, an immune checkpoint inhibitor releaving the brakes that prevent optimal T lymphocyte activation versus maintenance standard of care treatment with Folfiri.
The IND application has been submitted in France to the ANSM (the French National Agency for Medicines and Health Products Safety) and to the central Ethics Committee by the oncology cooperative group GERCOR, who is sponsoring the clinical trial as part of PRODIGE intergroup. The Company expects activation of the trial and opening of clinical centers in early 2019.
The Phase 2 clinical trial, named TEDOPaM, aims to evaluate Tedopi® as a maintenance therapy, alone or in combination with immune checkpoint inhibitor nivolumab, and evaluated versus Folfiri, a combination chemotherapy with folinic acid, fluorouracil and irinotecan and the standard of care. The study will be completed in HLA-A2 positive patients with stable disease who have received four months of first line standard-of-care chemotherapy Folforinox, a combination chemotherapy with folinic acid, fluorouracil, irinotecan and oxaliplatin.
"This new step marks the expansion of the development of Tedopi, already under evaluation in a Phase 3 study in advanced lung cancer, to an additional oncology indication, a particularly aggressive cancer for which new therapeutic options are strongly needed. With this new clinical development program evaluating Tedopi in combination with the PD-1 inhibitor nivolumab, a checkpoint inhibitor, in advanced pancreatic cancer, we are broadening our exploration of new pathways in immuno-oncology," commented Alexis Peyroles, chief executive officer of OSE Immunotherapeutics.
"The study's rationale is based on the interest of a combination of immunotherapies that stimulate cytotoxic T-cells with Tedopi, whose antigens are overexpressed in pancreatic tumor, and a PD-1 checkpoint inhibitor nivolumab, whose preclinical data available to date in this cancer plead in favor of a combination with a neoepitope-type immunotherapy, likely to potentiate its activity. Our network of clinicians is now mobilizing to start this Phase 2 trial," concluded Professor Christophe Louvet, president of GERCOR.
Tedopi is a combination of 10 neoepitopes selected and optimized from five tumor associated antigens able to generate a specific response against cytotoxic T-cells expressing at least one of these tumor associated antigens and an associated helper T-cell response.
ABOUT GERCOR
GERCOR is an association of physicians whose
purpose is to improve the care of patients affected by cancer by
developing clinical research in the scope of an independent,
multidisciplinary and multi-focused group. GERCOR concentrates its
efforts on only one mission: clinical research. Thanks to its network,
GERCOR offers patients easy access to its up-to-date treatments. To
achieve this goal, GERCOR stimulates the inclusion into its network of
the greatest number of physicians involved in the treatments it is
conducting, offers vital logistical assistance to research physicians
whose job is to direct and monitor the application of the treatments to
patients.
ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a
clinical-stage biotechnology company focused on developing and
partnering therapies to control the immune system for immuno-oncology
and autoimmmune diseases. The company has a diversified first-in-class
clinical portfolio consisting of several scientific and technological
platforms including neoepitopes and agonist or antagonist monoclonal
antibodies, all ideally positioned to fight cancer and autoimmune
diseases. Our most advanced asset, Tedopi®, is a proprietary
combination of 10 neo-epitopes aimed at stimulating T-lymphocytes and is
currently in Phase 3 development in non-small cell lung cancer (NSCLC)
after checkpoint inhibitor failure (anti PD-1 and anti PD-L1). In April
2018, Boehringer Ingelheim and OSE signed a global license and
collaboration agreement to develop checkpoint inhibitor OSE-172
(anti-SIRPa monoclonal antibody) in multiple cancer indications. In July
2016, Janssen Biotech exercised a licensing option to continue clinical
development of FR104 (an anti-CD28 mAb) in auto-immune diseases after
positive Phase 1 results. In 2016, Servier Laboratories signed a
two-step license option to develop OSE-127 (monoclonal antibody
targeting the CD127 receptor, the alpha chain of the interleukin-7
receptor) to develop the product up to the completion of a Phase 2
clinical trial planned in autoimmune bowel disease and Sjogren’s
syndrome.
Click and follow us on Twitter and Linkedln
Forward-looking statements
This press release contains
express or implied information and statements that might be deemed
forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are based
upon certain assumptions and assessments made by OSE Immunotherapeutics’
management in light of its experience and its perception of historical
trends, current economic and industry conditions, expected future
developments and other factors they believe to be appropriate.
These
forward-looking statements include statements typically using
conditional and containing verbs such as “expect”, “anticipate”,
“believe”, “target”, “plan”, or “estimate”, their declensions and
conjugations and words of similar import.
Although the OSE
Immunotherapeutics management believes that the forward-looking
statements and information are reasonable, the OSE Immunotherapeutics’
shareholders and other investors are cautioned that the completion of
such expectations is by nature subject to various risks, known or not,
and uncertainties which are difficult to predict and generally beyond
the control of OSE Immunotherapeutics. These risks could cause actual
results and developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by OSE
Immunotherapeutics with the AMF. Such forward-looking statements are not
guarantees of future performance.
This press release includes only
summary information and should be read with the OSE Immunotherapeutics
Reference Document filed with the AMF on 26 April 2018, including the
annual financial report for the fiscal year 2017, available on the OSE
Immunotherapeutics’ website.
Other than as required by applicable
law, OSE Immunotherapeutics issues this press release at the date hereof
and does not undertake any obligation to update or revise the
forward-looking information or statements.
